Takeda Pharmaceuticals, a Japan-based drugmaker, is voluntarily withdrawing Exkivity (mobocertinib) in the U.S. after a phase 3 trial failed to confirm the lung cancer drug’s efficacy.
Read the full post on Becker's Hospital Review - Healthcare News
